Art. -Nr.: HY-B0112

Minoxidil

(Synonyms: U10858)

11 Cited Publications

Kundenbewertung

Based on 11 publication(s) in Google Scholar

Minoxidil (U10858) is an ATP-sensitive potassium (K_ATP) channel opener, a potent oral antihypertensive agent and a peripheral vasodilator that promotes vasodilation also affects hair growth. Minoxidil is also a potent inhibitor of soybean lipoxygenaseare with an IC₅₀ of 20 μM.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.99%
CAS. Nr.: 38304-91-5
Formel: C₉H₁₅N₅O
Molecular Weight:209.25

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Minoxidil Chemical Structure

CAS. Nr.: 38304-91-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (11)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

IC50: 20 μM (soybean lipoxygenaseare)^[1]; ATP-sensitive potassium channel^[2]

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
HL-60	IC₅₀	>10 μM Compound: MNX	Induction of cell differentiation in human HL60 cells by NBT/MTT assay Induction of cell differentiation in human HL60 cells by NBT/MTT assay	[PMID: 26832215]

In Vitro

Minoxidil (1-00 μM; 24 hours; RAMEC cells) treatment shows very low cytotoxicities in the whole area of concentrations examined (from 1 μM to 100 μM)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Minoxidil (0.01 mmoL/kg body weight; intraperitoneal injection; for 3.5 hours; fisher 344 rats) treatment inhibits carrageenan-induced rat paw oedema with an inhibitory potency (49%)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Fisher 344 rats (150-200 g) with oedema^[1]
Dosage:

0.01 mmol/kg body weight
Administration:

Intraperitoneal injection; for 3.5 hours
Result:

Inhibition of the carrageenin-induced oedema.

Chemical Information

CAS. Nr. 38304-91-5
Appearance Solid
Molecular Weight 209.25
Formel C₉H₁₅N₅O
Color White to off-white
SMILES

NC1=NC(N2CCCCC2)=CC(N)=[N+]1[O-]
Synonyms

U10858
Structure Classification
- Alkaloids
- Piperidine Alkaloids
Initial Source
- Endogenous metabolite
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (11)

All Cell Imaging/StainingWBHistological Imaging/StainingCell Proliferation/Viability AssayIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Cell Stem Cell

Kidney organoid models reveal cilium-autophagy metabolic axis as a therapeutic target for PKD both in vitro and in vivo. [Abstract]

2024 Jan 4;31(1):52-70.e8. PMID: 38181751

Minoxidil purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. [Abstract]

Representative bright-field images of ARPKD (ARPKD Epi-17) kidney organoids treated with a concentration gradient of ST034307 and Minoxidil (0.1-5 μM) in the presence of FSK for 3 days. Scale bars, 200 μm.

Minoxidil purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2024 Jan 4;31(1):52-70.e8. [Abstract]

Minoxidil (i.p.; once daily for 3 weeks) administered at 1 and 5 mg/kg/day reduced the calculated cystic index of ARPKD kidney organoid xenografts from host NSG mice by 18.85% and 33.93%, respectively.
Bioact Mater

Sustainability of functional hair follicle activity: Impact of spatially anchored multifunctional tetrahedral framework nucleic acids. [Abstract]

2025 Nov 14:57:344-357. PMID: 41323202

Minoxidil purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 14:57:344-357. [Abstract]

Cell proliferation assay in DPCs and HFSCs treated with DHT (500 μM) and DHT combined with Minoxidil (20 μM), tFNFs (0.25 μM), Que (20 μM), and TQC (tFNFs/Que: 0.25/20 μM) for 24 h.

Minoxidil purchased from MedChemExpress. Usage Cited in: Bioact Mater. 2025 Nov 14:57:344-357. [Abstract]

Time-course observations of hair growth of samples at 1, 4, 7, 10, 14, 15, 18, 21, 24, and 28 days (n = 5). The results showed that Minoxidil (5%; topical application, 100 μL per application) treatment, serving as a positive control, led to gradual hair regrowth starting from day 10, with marked hair coverage observed by day 28.
J Adv Res

Targeting PLOD2 induces epithelioid differentiation and improves therapeutic response in sarcomatoid renal cell carcinoma. [Abstract]

2025 Oct 16:S2090-1232(25)00818-5. PMID: 41109566

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (0.5 mM； 48 h) led to a significant increase in the expression of epithelial differentiation markers in 786-O sccRCC cells.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (0.25-0.5 mM; 48 h) did not cause substantial 786-O ccRCC cell death.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (6 mg/kg; gavage) significantly reduced the Ki-67 index in sccRCC xenograft mouse models.

Minoxidil purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Oct 16:S2090-1232(25)00818-5. [Abstract]

Minoxidil (6 mg/kg; gavage) significantly reduced the tumor growth rate in sccRCC xenograft mouse models.
Phytomedicine

Deoxyshikonin from Arnebiae Radix promotes hair growth by targeting the Wnt/β-catenin signaling pathway. [Abstract]

2025 May:140:156590. PMID: 40049105
Cell Rep

miR-24 controls the regenerative competence of hair follicle progenitors by targeting Plk3. [Abstract]

2021 Jun 8;35(10):109225. PMID: 34107258
J Med Chem

A Top-Down Design Approach for Generating a Peptide PROTAC Drug Targeting Androgen Receptor for Androgenetic Alopecia Therapy. [Abstract]

2024 Jun 27;67(12):10336-10349. PMID: 38836467
Antioxidants (Basel)

Schizochytrium sp. Extracted Lipids Prevent Alopecia by Enhancing Antioxidation and Inhibiting Ferroptosis of Dermal Papilla Cells. [Abstract]

2023 Jun 23;12(7):1332. PMID: 37507872
Drug Des Devel Ther

New Target for Minoxidil in the Treatment of Androgenetic Alopecia. [Abstract]

2023 Aug 24:17:2537-2547. PMID: 37645625
Dermatol Clin

2024 September 12.
Biomed Res Int

Effects of Baicalin on Alopecia and the Associated Mechanism. [Abstract]

2022 Nov 18:2022:3139123. PMID: 36440360
Sys Rev Pharm

2021;12(1):402-410.

Lösungsmittel & Löslichkeit

In Vitro:

Ethanol : 7.14 mg/mL (34.12 mM; Need ultrasonic)

DMSO : 5 mg/mL (23.89 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 1 mg/mL (4.78 mM; ultrasonic and warming and heat to 50°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.7790 mL

23.8949 mL

47.7897 mL

5 mM

0.9558 mL

4.7790 mL

9.5579 mL

10 mM

0.4779 mL

2.3895 mL

4.7790 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil

Solubility: ≥ 0.71 mg/mL (3.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.71 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (7.1 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (2.39 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 1.96 mg/mL (9.37 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Protocol 2

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 5 mg/mL (23.89 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Hadjipavlou-Litina D, et al. Synthesis and evaluation of the antioxidative potential of minoxidil-polyamine conjugates. Biochimie. 2013 Jul;95(7):1437-49. doi: 10.1016/j.biochi.2013.03.009. Epub 2013 Mar 28. [Content Brief]

[2]. Davies GC, et al. Novel and established potassium channel openers stimulate hair growth in vitro: implications for their modes of action in hair follicles. J Invest Dermatol. 2005 Apr;124(4):686-94. [Content Brief]

[3]. Cohen RL, et al. Direct effects of minoxidil on epidermal cells in culture. J Invest Dermatol. 1984 Jan;82(1):90-3. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO / Ethanol	1 mM	4.7790 mL	23.8949 mL	47.7897 mL	119.4743 mL
DMSO / Ethanol	5 mM	0.9558 mL	4.7790 mL	9.5579 mL	23.8949 mL
	10 mM	0.4779 mL	2.3895 mL	4.7790 mL	11.9474 mL
	15 mM	0.3186 mL	1.5930 mL	3.1860 mL	7.9650 mL
	20 mM	0.2389 mL	1.1947 mL	2.3895 mL	5.9737 mL
Ethanol	25 mM	0.1912 mL	0.9558 mL	1.9116 mL	4.7790 mL
Ethanol	30 mM	0.1593 mL	0.7965 mL	1.5930 mL	3.9825 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Minoxidil

11 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Minoxidil

Membrane Transporter/Ion Channel Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Anti-Cardiovascular Disease Compound Library

Anti-COVID-19 Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Neuroprotective Compound Library

Alkaloids Library

Rare Diseases Drug Library

Potassium Channel Compound Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Off-patent Drug Library

Antihypertensive Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Ion Channel Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

RO5 Drug-like Natural Product Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Cardiotoxic Compound Library

Natural Product Diversity Scaffold Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Minoxidil

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (11)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Minoxidil Related Classifications

Art. -Nr.: HY-B0112